atropine sulfate; edrophonium chloride
ENLON-PLUS (atropine sulfate; edrophonium chloride) is muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Approved for older for: atropine is an anticholinergic agent indicated in adults, older for: cycloplegia () mydriasis () penalization of the healthy eye in the treatment of amblyopia () 1. First approved in 1991.
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
ENLON-PLUS is a fixed-dose combination injectable containing atropine sulfate (anticholinergic) and edrophonium chloride (cholinesterase inhibitor) approved in 1991. It is indicated for cycloplegia, mydriasis, and penalization of the healthy eye in amblyopia treatment. The atropine component blocks muscarinic receptors to prevent pupillary constriction and ciliary muscle contraction, while edrophonium enhances acetylcholine availability.
Product is nearing loss of exclusivity with moderate competitive pressure (30), signaling potential team contraction or redeployment of commercial talent.
muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does…
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moENLON-PLUS offers limited career growth due to LOE approach and minimal linked job postings. Roles are maintenance-focused rather than growth-oriented, making this a consolidation or wind-down assignment rather than a career accelerator.